Detalhe da pesquisa
1.
Exploitation of dihydroorotate dehydrogenase (DHODH) and p53 activation as therapeutic targets: A case study in polypharmacology.
J Biol Chem;
295(52): 17935-17949, 2020 12 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32900849
2.
Correction: Modulation of p53 C-Terminal Acetylation by Mdm2, p14ARF, and Cytoplasmic SirT2.
Mol Cancer Ther;
22(12): 1503, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38037420
3.
Lipids Shape the Electron Acceptor-Binding Site of the Peripheral Membrane Protein Dihydroorotate Dehydrogenase.
Cell Chem Biol;
25(3): 309-317.e4, 2018 03 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29358052
4.
Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib.
PLoS One;
13(4): e0195956, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29684045
5.
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Nat Commun;
9(1): 2071, 2018 05 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29789663
6.
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Nat Commun;
9(1): 1107, 2018 03 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29549331
7.
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Nat Commun;
14(1): 5019, 2023 Aug 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37596290
8.
Towards a multiscale model of colorectal cancer.
World J Gastroenterol;
13(9): 1399-407, 2007 Mar 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17457972
9.
A general model for multiple substrate biodegradation. Application to co-metabolism of structurally non-analogous compounds.
Water Res;
37(20): 4843-54, 2003 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14604630
10.
Modelling microbial adaptation to changing availability of substrates.
Water Res;
38(4): 1003-13, 2004 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-14769420
11.
Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2.
Mol Cancer Ther;
12(4): 471-80, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23416275
12.
Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner.
Mol Cancer Ther;
12(4): 352-60, 2013 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23322738
13.
Cyclotherapy: opening a therapeutic window in cancer treatment.
Oncotarget;
3(6): 596-600, 2012 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22711025
14.
An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells.
Cell Cycle;
11(9): 1851-61, 2012 May 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22517433
15.
Mechanism-specific signatures for small-molecule p53 activators.
Cell Cycle;
10(10): 1590-8, 2011 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21490429
16.
Dynamic energy budget approaches for modelling organismal ageing.
Philos Trans R Soc Lond B Biol Sci;
365(1557): 3443-54, 2010 Nov 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20921044
17.
Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.
Oncotarget;
1(7): 639-50, 2010 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21317459
18.
Elucidating the interactions between the adhesive and transcriptional functions of beta-catenin in normal and cancerous cells.
J Theor Biol;
247(1): 77-102, 2007 Jul 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-17382967
19.
Pharmacological manipulation of the cell cycle and metabolism to protect normal tissues against conventional anticancer drugs.
Oncotarget;
2(4): 274-6, 2011 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21512204